Drug-Induced Torsade de Pointes. From Molecular Biology to Bedside.
Key result
QT-prolonging drugs cause torsades de pointes by blocking cardiac K+ channels, particularly IKr, which may represent an iatrogenic reproduction of congenital long QT syndrome.
Why the study?
What are the mechanisms, risk factors, and management strategies for drug-induced Torsades de Pointes?
Population
Patients at risk for or experiencing drug-induced QT prolongation and Torsades de Pointes, including those…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Clinicians should monitor QT with IKr blockers to avert TdP; reinforces mechanism-based arrhythmia risk assessment.
Structured PICO
What are the mechanisms, risk factors, and management strategies for drug-induced Torsades de Pointes?
P
Population
Patients at risk for or experiencing drug-induced QT prolongation and Torsades de Pointes, including those with silent forms of congenital LQTS.
E
Exposure
QT-prolonging drugs (cardiac and noncardiac)
O
Outcome
Development of QT prolongation and Torsades de Pointes (TdP)safety
This review highlights that drug-induced Torsades de Pointes is often an iatrogenic unmasking of congenital long QT syndrome via IKr channel blockade, emphasizing the need for careful prescribing and risk management.
Cite This Study
Juan Tamargo (2000) conducted a review in Drug-induced Torsade de Pointes. QT-prolonging drugs was evaluated. QT-prolonging drugs cause torsades de pointes by blocking cardiac K+ channels, particularly IKr, which may represent an iatrogenic reproduction of congenital long QT syndrome.